在急性髓性白血病中,用于协同mRNA和siRNA代码交付的结构活动驱动的多分部脂质纳米粒子
Xiaofei Xin1,2, Yifu Lyu3, Huanyu Qin1
1Department of Pharmaceutics, China Pharmaceutical University, Nanjing 210009, China.
Journal of the American Chemical Society
|February 20, 2026
概括
基于伊米达的新型脂质纳米粒子 (LNPs) 具有无序的海绵状结构,可以有效地编码mRNA和siRNA. 这些LNP增强细胞吸收和免疫反应,显示了癌症免疫治疗的前景.
科学领域:
- 生物技术是生物技术.
- 纳米医学是一种纳米医学.
- 免疫学 免疫学 免疫学
背景情况:
- 非状的多分层脂质纳米颗粒 (LNP) 对于核酸输送和免疫治疗至关重要.
- 对LNP的合理设计可以优化其内部结构,以提高治疗效果.
研究的目的:
- 开发基于伊米达的LNP (A3-DM/DL-LNP) 具有无序的海绵状内部结构.
- 使用这些新型LNP,评估mRNA和STAT3向siRNA (siSTAT3) 的代码传递.
- 评估A3-DM/DL-LNP在急性髓性白血病 (AML) 免疫治疗中的治疗潜力.
主要方法:
- 微角散射分析以描述LNP结构和内部布局.
- 拉曼光谱法用于将脂质定位与免疫器官中的RNA表达相关联.
- 在体外和体内研究评估细胞吸收,传染效率和抗白血病活性.
主要成果:
- A3-DM/DL-LNPs表现出一种独特的准周期安排,增强了膜异质性,促进了内细胞和RNA封装.
- 与线性头组LNP相比,A3-DM/DL-LNP的"M形"极点头组改善了膜相互作用,细胞吸收和转染效率.
- A3-DM/DL-LNPs恢复了树突细胞抗原呈现,缓解了ER压力,逆转了AML中的T细胞耗尽,并增强了NK和T细胞介导的抗白血病活性.
结论:
- 基于伊米达的LNP的合理设计,具有无序的内部结构,使mRNA和siRNA的有效代码传递成为可能.
- 伦比NP结构显著影响免疫激活和器官向,与治疗结果相关联.
- 通过增强抗白血病免疫反应,A3-DM/DL-LNP显示出强大的AML免疫治疗潜力.
相关概念视频
Modified-Release Drug Delivery Systems: Site-Targeted
33
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
33
Site-Targeted Drug Delivery Systems: Polymeric Carriers
36
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
36


